Plan B Ruling Sets A Precedent That Could Give FDA Pause
This article was originally published in The Pink Sheet Daily
March 23 ruling ordered FDA to reconsider a citizen petition requesting Plan B access for women of all ages.
You may also be interested in...
The question of how to enforce an age-limit for OTC availability of Barr Labs' Plan B - rather than whether dual status for the drug could exist at all - was the main driver behind FDA's initiation of a rulemaking on the Rx-to-OTC switch application for the emergency contraceptive, according to former FDA Commissioner Lester Crawford
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.
Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.